Johns Hopkins Institute for Clinical and Translational Research

约翰·霍普金斯临床与转化研究所

• 批准号: 9892396
• 负责人: Daniel Ernest Ford
• 金额: $ 1538.89万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-05-31 至 2024-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9892396
• 关键词: Accident and Emergency department; Address; Admission activity; Alzheimer' s Disease; American; Baltimore; Budgets; Clinic; Clinical Research; Collaborations; Communication; Communities; Complex; Conduct Clinical Trials; Consultations; Country; Data; Databases; Diagnosis; Disease; Ecosystem; Engineering; Environment; Funding; Goals; Health; Health Promotion; Health Status; Health system; Healthcare; Healthcare Systems; Home environment; Hospitals; Incentives; Individual; Informatics; Information Systems; Institutes; Institution; Insurance; Interdisciplinary Study; Intervention; Joints; Laboratories; Lead; Leadership; Learning; Maryland; Measurable; Medicare; Mentors; Methodology; Mission; Modeling; Multiple Partners; Obesity; Outcome; Pathway interactions; Patients; Pharmacy Schools; Phase; Population; Population Group; Population Heterogeneity; Prevention; Public Health; Randomized Clinical Trials; Research; Research Personnel; Research Support; Research Training; Resources; Safety; Science; Scientist; Services; Sexually Transmitted Diseases; Specialist; Speed; Substance abuse problem; Technology; Training; Training Programs; Translating; Translational Research; Translations; Universities; Vision; Work; care outcomes; clinical infrastructure; drug development; drug discovery; effective therapy; experience; global health; health care availability; health care delivery; health disparity; improved; individual patient; innovation; investigator training; multidisciplinary; next generation; novel therapeutics; patient population; population health; precision medicine; programs; skills; translational scientist; waiver

The Johns Hopkins Institute for Clinical and Translational Research (ICTR) has been a productive, innovative and impactful organization in transforming how clinical and translational research is conducted throughout Johns Hopkins University. Enhancing collaborative research teams, advancing informatics, promoting new methodologies, providing access to regulatory support, and bringing researchers and the community closer together as true partners in discovery have all made translational research more successful. Over the next five years, the Johns Hopkins ICTR will move beyond its current research community to create a comprehensive regional hub that includes new partners – the University of Maryland Baltimore (UMB), Morgan State University (MSU) and Kaiser Permanente Mid-Atlantic States (KPMAS). These partners bring complementary expertise and connections to distinct populations. Together, we have an opportunity to conduct high quality innovative research, and rapidly implement findings that impact the health of our state and region. Building on our extensive connections with community groups, we will move to a new phase of joint governance with bidirectional communication and participation on key ICTR committees. New programs will include a Trial Innovation Unit that will focus on improving methodologic and operational support for research teams conducting randomized clinical trials so that the impact of these trials is enhanced. A goal of this Unit will be to pilot and disseminate approaches that move randomized clinical trials closer to the precision medicine paradigm, with a focus on outcomes of greatest value to individual patients. Combining drug discovery scientists at Johns Hopkins with experts at the UMB School of Pharmacy, the ICTR will create a new Drug Discovery and Development Core. KPMAS and Johns Hopkins will continue to jointly fund programs that push the boundaries of how a Learning Health Care system can improve health outcomes. The ICTR provides a model for training investigators to work in multidisciplinary teams with experienced mentors using the most rigorous methodologies. We will enhance our training programs by incorporating principles of biodesign from the engineering tradition into the experience of all trainees. This places a higher emphasis on identification of the problem, engaging important stakeholders (clinicians, patients, IT professionals) to develop solutions, and identifying the most effective pathways to dissemination. Translational research demands the skills of many professionals working together to address complex problems. The Johns Hopkins ICTR is poised to leverage our current services to benefit new partners who have extensive responsibility for the conduct of research and health care delivery in Maryland. Working together, we expect to have a measurable impact on translational research in Maryland.

约翰霍普金斯临床和转化研究所（ICTR）一直是一个富有成效的，创新的 和有影响力的组织，改变临床和转化研究的进行方式， 约翰霍普金斯大学。加强合作研究团队，推进信息学，促进新的 方法，提供获得监管支持的机会，并使研究人员和社区更加紧密 作为发现的真正合作伙伴，所有这些都使转化研究更加成功。在未来五 未来几年，约翰霍普金斯国际刑事法庭将超越其目前的研究界， 一个区域中心，包括新的合作伙伴-马里兰州巴尔的摩大学（UMB），摩根州立大学 (MSU)Kaiser Permanente Mid-Atlantic States（KPMAS）这些合作伙伴带来了互补的专业知识 与不同人群的联系我们一起有机会进行高质量的创新 研究，并迅速实施影响我们国家和地区健康的发现。充分发挥两国 与社区团体的广泛联系，我们将进入共同治理的新阶段， 双向沟通和参与卢旺达问题国际法庭的主要委员会。新计划将包括一个审判 创新股，将侧重于改善对研究团队的方法和业务支持 进行随机临床试验，以提高这些试验的影响。该股的目标是 试点和推广使随机临床试验更接近精准医学的方法 范式，重点是对个体患者最有价值的结果。结合药物发现 约翰霍普金斯大学的科学家与UMB药学院的专家一起，卢旺达问题国际法庭将创造一种新的药物 发现和发展核心。KPMAS和约翰霍普金斯将继续联合资助项目， 学习保健系统如何改善健康结果的界限。卢旺达问题国际法庭提供了 培训研究人员在多学科团队中工作的模式，有经验丰富的导师， 严格的方法。我们将加强我们的培训计划，纳入生物设计的原则， 将工程传统融入所有学员的体验中。这就更加强调识别 问题，让重要的利益相关者（临床医生、患者、IT专业人员）参与制定解决方案，以及 确定最有效的传播途径。翻译研究需要许多人的技能 专业人士一起解决复杂的问题。约翰霍普金斯卢旺达问题国际法庭准备利用 我们目前的服务，使新的合作伙伴谁拥有广泛的责任进行研究和 马里兰州的医疗保健服务。通过共同努力，我们希望对翻译产生可衡量的影响， 在马里兰州做研究。